ImageneBio

ImageneBio Inventory Turnover

Inventory Turnover Ratio of ImageneBio (IMA) as of Oct 18, 2026.

Inventory Turnover

-

Last updated:

Inventory Turnover Ratio of ImageneBio is 2026 - . Inventory Turnover Ratio of ImageneBio was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImageneBio Stock analysis

What does ImageneBio do? ImageneBio Inc, based in Boston, US, is a targeted oncology company focused on developing cancer therapies. It operates in the health care sector, targeting signaling pathways involved in cancer formation and spread. The company's lead product candidate, IK-930, inhibits the TEAD transcription factor in the Hippo signaling pathway. ImageneBio also develops programs targeting ERK5, RAS pathways, and the tumor microenvironment, with multiple candidates in clinical and discovery stages. Listed on March 26, 2021, it employs 15 full-time staff. ImageneBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImageneBio stock

On Eulerpool you can find the complete historical development of Inventory Turnover Ratio ImageneBio since 2006 – with annual values, charts, and detailed analysis.

Inventory turnover measures how many times inventory is sold and replaced during a period. Higher turnover indicates efficient inventory management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Inventory Turnover Ratio's ImageneBio with sector peers and the industry average to assess whether it is attractive.

To evaluate Inventory Turnover Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Inventory Turnover Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — ImageneBio

All Key Metrics — ImageneBio